Literature DB >> 708

The cholinergic system and nociception in the primate: interactions with morphine.

A Pert.   

Abstract

In Experiment 1 the shock titration task was used to evaluate the antinoceptive properties of 5 different classes of cholinergic compounds in the rhesus monkey. Only scopolamine and high doses of physostigmine were effective in elevating the shock threshold. The apparent antinociceptive effect of physostigmine, however, was difficult to separate from its nonspecific behavioral depressant effect and was probably not related to an increase in cholinergic tone. Experiment 2 examined the interaction of morphine with arecoline, scopolamine and physostigmine. Only scopolamine (0.05 and 0.1 mg/kg) and high doses of physostigmine (0.1 mg/kg) interacted with morphine in the shock titration paradigm. The multiplicative interaction of morphine with scopolamine was confirmed in Experiment 3 over a wider range of doses. It was concluded that morphine and the cholinergic compounds produce antinociceptive effects through different mechanisms of the pain system.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 708     DOI: 10.1007/BF00420999

Source DB:  PubMed          Journal:  Psychopharmacologia


  17 in total

1.  DEPRESSION BY MORPHINE AND CHLORALOSE OF ACETYLCHOLINE RELEASE FROM THE CAT'S BRAIN.

Authors:  D BELESLIN; R L POLAK
Journal:  J Physiol       Date:  1965-04       Impact factor: 5.182

2.  The effects of certain drugs on cerebral synapses.

Authors:  A S MARRAZZI
Journal:  Ann N Y Acad Sci       Date:  1957-03-14       Impact factor: 5.691

3.  The effects of arecoline on spinal reflexes of the cat.

Authors:  A H Tang; G K Yim
Journal:  Int J Neuropharmacol       Date:  1965-11

4.  Narcotic-antagonist analgesics: interactions with cholinergic systems.

Authors:  L S Harris; W L Dewey; J F Howes; J S Kennedy; H Pars
Journal:  J Pharmacol Exp Ther       Date:  1969-09       Impact factor: 4.030

5.  Acetylcholinesterase inhibition and morphine effects in morphine tolerant and dependent mice.

Authors:  H N Bhargava; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1972-10       Impact factor: 4.030

6.  The effects of scopolamine and pilocarpine upon the aversive threshold of the rat.

Authors:  V P Houser; D A Van Hart
Journal:  Pharmacol Biochem Behav       Date:  1973 Jul-Aug       Impact factor: 3.533

7.  Studies on the central antinociceptive action of cholinomimetic agents.

Authors:  J Metys; N Wagner; J Metysová; A Herz
Journal:  Int J Neuropharmacol       Date:  1969-09

8.  Comparison of analgesic, cholinomimetic, anticholinergic and sympathomimetic drugs by means of the hot-plate test.

Authors:  A J van Eick; J Bock
Journal:  Arch Int Pharmacodyn Ther       Date:  1971-02

9.  Comparison of the antinociceptive activities of physostigmine, oxotremorine and morphine in the mouse.

Authors:  B J Pleuvry; M A Tobias
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

10.  A comparison of the antinociceptive actions of cholinomimetic and morphine-like drugs.

Authors:  J D Ireson
Journal:  Br J Pharmacol       Date:  1970-09       Impact factor: 8.739

View more
  4 in total

1.  Asymmetrical cross-tolerance between morphine and scopolamine induced antinociception in the primate: differential sites of action.

Authors:  A Pert; G Maxey
Journal:  Psychopharmacologia       Date:  1975-10-31

2.  Antinociceptive effects of central and systemic administrations of nicotine in the rat.

Authors:  T L Sahley; G G Berntson
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

3.  Selective potentiations in opioid analgesia following scopolamine pretreatment.

Authors:  E S Sperber; M T Romero; R J Bodnar
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Involvement of hippocampal acetylcholinergic receptors in electroacupuncture analgesia in neuropathic pain rats.

Authors:  Shu Ping Chen; Yu Kan; Jian Liang Zhang; Jun Ying Wang; Yong Hui Gao; Li Na Qiao; Xiu Mei Feng; Ya Xia Yan; Jun Ling Liu
Journal:  Behav Brain Funct       Date:  2016-04-12       Impact factor: 3.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.